ArticleHaematologica2019
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.
Open access · goldAbstract read
In one paragraph
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis.Annals of hematology · 2025Pooled it
- Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.Leukemia · 2025Article
- Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.Annals of hematology · 2024Article
- Increased abundance ofOncology letters · 2024Article
- A personalized stepwise dynamic predictive algorithm of the time to first treatment in chronic lymphocytic leukemia.iScience · 2023Article
- A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements.Haematologica · 2023Article
- Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors.Genes · 2023Article
- Article
- Precision diagnostics in chronic lymphocytic leukemia: Past, present and future.Frontiers in oncology · 2023Review
- Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles.Frontiers in oncology · 2023Article
- CLL-IPI applied in Binet A CLL: a nationwide cohort study.Blood advances · 2022Article
- Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.Nature communications · 2022Article
- Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients.Annals of hematology · 2022Article
- Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity.Frontiers in oncology · 2022Article
- Landscape of TP53 Alterations in Chronic Lymphocytic LeukemiaFrontiers in oncology · 2022Review
- The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.Diagnostics (Basel, Switzerland) · 2021Review
- From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.Cancers · 2021Review
- Article
- Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 20 institutions in 8 countries.
Panagiotis BaliakasDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Theodoros MoysiadisInstitute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
Anastasia HadzidimitriouDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Aliki XochelliDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Sabine JerominMLL Munich Leukemia Laboratory, Munich, Germany.
Andreas AgathangelidisInstitute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
Mattias MattssonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Lesley-Ann SuttonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Eva MingaInstitute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
Lydia ScarfòDivision of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
Davide RossiOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Zadie DavisDepartment of Haematology, Royal Bournemouth Hospital, UK.
Neus VillamorHemopathology Unit, Hospital Clinic, Barcelona, Spain.
Helen ParkerCancer Genomics, Academic Unit of Cancer Sciences, Cancer Research UK Centre and Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, UK.
Jana KotaskovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Evangelia StalikaInstitute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
Karla PlevovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
Larry MansouriDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Diego CorteseDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Alba NavarroHemopathology Unit, Hospital Clinic, Barcelona, Spain.
Julio DelgadoHematology Department, Hospital Clinic, Barcelona, Spain.
Marta LarrayozCancer Genomics, Academic Unit of Cancer Sciences, Cancer Research UK Centre and Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, UK.
Emma YoungDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Achilles AnagnostopoulosHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Karin E SmedbyDepartment of Medicine, Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.
Gunnar JuliussonLund University and Hospital Department of Hematology, Lund Stem Cell Center, Sweden.
Oonagh SheehyDepartment of Hemato-Oncology, Belfast City Hospital, UK.
Mark CatherwoodDepartment of Hemato-Oncology, Belfast City Hospital, UK.
Jonathan C StreffordCancer Genomics, Academic Unit of Cancer Sciences, Cancer Research UK Centre and Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, UK.
Niki StavroyianniHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Chrysoula BelessiHematology Department, Nikea General Hospital, Pireaus, Greece.
Sarka PospisilovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
David OscierDepartment of Haematology, Royal Bournemouth Hospital, UK.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Elias CampoHemopathology Unit, Hospital Clinic, Barcelona, Spain.
Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Paolo GhiaDivision of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
Richard RosenquistDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Kostas StamatopoulosDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden kostas.stamatopoulos@gmail.com.
European Research Initiative on CLL (ERIC)
Centre for Research and Technology Hellas · GRUppsala University · SECancer Research UK · GBHospital Clínic de Barcelona · ESScience for Life Laboratory · SECentral European Institute of Technology · CZG. Papanikolaou General Hospital · GRKarolinska Institutet · SEMunich Leukemia Laboratory (Germany) · DERoyal Bournemouth Hospital · GBBelfast City Hospital · GBCentral European Institute of Technology – Masaryk University · CZGeneral Hospital of Nikea · GRInstitute of Oncology Research · CHIstituti di Ricovero e Cura a Carattere Scientifico · ITLund University · SEUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversitat de Barcelona · ESUniversity of Ulster · GBVita-Salute San Raffaele University · IT
Funding
Cancer Research UK 23669
Abstract
Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides
Indexed as
Biomarkers, TumorDisease SusceptibilityAgedAged, 80 and overChromosome AberrationsFemaleHumansImmunogeneticsKaplan-Meier EstimateLeukemia, Lymphocytic, Chronic, B-CellMaleMutationNeoplasm StagingPrognosisTime-to-TreatmentBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.